INNOVATIVE LIQUID BIOPSY METHOD USING LAB-ON-ACHIP TECHNOLOGY FOR CANCER DIAGNOSIS AND MANAGEMENTbroad
LUMEN · Horizon Europe grant · 2024-11-01–2026-10-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2024-ACCELERATOROPEN-01. CORDIS record →
Objective
JaxBio is a pioneering biotech startup company dedicated to transforming lung cancer diagnostics and treatment through innovative liquid biopsy and DNA-chip technology. Our team, comprised mainly of Ph.D. experts in cancer biology, data science, and technology development, is committed to addressing the critical challenge of early lung cancer detection and management. The global impact of lung cancer, claiming nearly 1.8 million lives annually, highlights the urgent need for advanced diagnostic solutions. Over 70% of lung cancer patients are diagnosed at advanced stages, resulting in poor prognosis and high mortality rates. Furthermore, approximately 50% of patients receive suboptimal treatment due to a lack of methods to predict treatment response rapidly. JaxBio addresses these challenges with LUMEN, an innovative non-invasive liquid biopsy assay. This method employs a custom chip designed for ultra-sensitive detection of epigenetic signatures in cell-free DNA, complemented by an AI algorithm for identifying disease-specific biomarkers. Our findings demonstrate LUMEN's ability to detect cancer early, even with extremely low tumor-derived DNA concentrations in the blood. Eliminating the need for DNA sequencing, LUMEN offers unparalleled accuracy in cancer detection as well as affordability. It also provides valuable insights for personalized treatment approaches and early tumor recurrence detection. With EIC support, our objective is to conduct clinical trials and complete the development of the lung cancer chip. This chip will serve as a companion diagnostic tool, predicting therapy response, and assessing treatment effectiveness. Our goal is to bring a clinically validated product to market, comprising reagents, chips, and analysis software, ultimately enhancing cancer care and patient outcomes.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| JAXBIO TECHNOLOGIES LTD | IL | coordinator | €2,493,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.